This website is for UK Healthcare Professionals only

*Remission is based on CR, ORR and PR. CR is defined in the SmPC as complete remission.
UK-VNCCLL-220184 | May 2022

Dosing schedules for VENCLYXTO combination regimens

VENCLYXTO combinations are designed to give your CLL patients a chance to take their life back with a fixed treatment duration.1-5

The 5-week dose-titration schedule is designed to gradually reduce tumour burden (debulk) and decrease the risk of TLS. 1

*Each cycle is 28 days.
†Administered orally. Start the 5-week VENCLYXTO dose titration schedule on cycle 1 day 22.
‡100 mg on cycle 1 day 1, followed by 900 mg, which may be administered on day 1 or 2.
IV = intravenous; Ven+O= VENCLYXTO + obinutuzumab.

*Each cycle is 28 days.
†Administered orally.
IV = intravenous; Ven+R = VENCLYXTO + rituximab.


* The modified dose should be continued for 1 week before increasing the dose.

A larger dose reduction may occur at physicians discretion.

Consider discontinuation of VENCLYXTO if patients have to be dose-reduced to less than 100 mg for more than two weeks.

* The modified dose should be continued for 1 week before increasing the dose.


CLL=Chronic lymphocytic leukaemia; CR=Complete remission; ORR=Overall response rate; PR=Partial response; SmPC=Summary of product characteristics.

References

  1. VENCLYXTO Summary of Product Characteristics.
  2. Seymour JF et al. N Engl J Med. 2018; 378(12): 1107–20.
  3. Fischer K et al. N Engl J Med. 2019; 380: 2225–36.
  4. Leukaemia Care Living with Leukaemia 2018 Report https://media.leukaemiacare.org.uk/wp-content/uploads/Living-with-Leukaemia-2018-Full-Report_compressed.pdf (accessed May 2022).
  5. Al-Sawaf O et al. Am J Hematol. 2021; 96(9): 1112-19. doi: 10.1002/ajh.26260.

 

 

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to AbbVie on GBPV@abbvie.com

UK-VNCCLL-220191. Date of preparation: May 2022.